The Expression And Clinical Significance Of GPR50 And ADAM17 In Breast Cancer

Objectives To study the expression of G protein-coupled receptor 50(GPR50)and A disintegrin and metalloproteinase 17(ADAM17)in human breast cancer(BC)tissue,and to investigate the correlation between the two and the clinicopathological factors(age,tumor size,lymph node metastasis,Statistical analysis was conducted to investigate the correlation and clinical significance of GPR50 and ADAM17 expression in breast cancer.Methods Complete case data of breast cancer and breast fibronenoma confirmed by postoperative pathology in the Affiliated Hospital of North China University of Science and Technology were selected from January 1,2018 to October 31,2020.182 cases of breast cancer were all collected in group,In the breast fibroadenoma group and normal tissue adjacent to breast cancer group,30 cases were randomly selected into each group.Immunohistochemical staining was used to detect GPR50 and ADAM17 expression positive rate;Western blot was conducted to determine the relative GPR50 and ADAM17 protein expression.The expression of GPR50 and ADAM17 in cancer tissues and their correlation with clinicopathological features were analyzed.Results 1 Immunohistochemical results of GPR50 showed that the positive rate of GPR50 in breast cancer group was significantly lower than that in fibronenoma group and paracancerous group(P<0.05).Notably,the positive rate of GPR50 in fibronenoma group was significantly higher than that in paracancerous group(P<0.05);2Immunohistochemical results of ADAM17 showed that the expression of ADAM17 was significantly increased in the breast cancer group compared with the fibronenoma group and the paracancerous group(P<0.05).There was no significant difference in the positive rate of ADAM17 between the paracancerous group and the fibronenoma group(P>0.05);3Western blot analysis of the protein expression levels of GPR50 and ADAM17: the protein expression level of GPR50 was significantly decreased in the breast cancer group,and the difference was statistically significant compared with the fibronenoma group and the paracancerous group(P<0.05),the expression of GPR50 in fibronenoma group was significantly higher than that in paracancerous group(P<0.05);Compared with the fibronenoma group and the paracancerous group,the protein expression of ADAM17 was significantly decreased in the breast cancer group,showing a statistically significant difference(P<0.05);4 Data analysis of breast cancer patients showed that the expression of GPR50 in breast cancer was correlated with lymph node metastasis,histological grade,PR,HER-2 and Ki-67 expression,and the expression level of GPR50 was lower with the higher malignant degree of tumor(P<0.05).The expression of ADAM17 in breast cancer was correlated with lymph node metastasis,histological grade,Her-2 and Ki-67 expression,and the higher the malignant degree of tumor,the higher the expression of ADAM17(P<0.05);5 The correlation between the expression of GPR50 and ADAM17 in breast cancer was further analyzed.Spearman rank correlation test was used to conduct pairwise correlation analysis,and the results showed that there was a significant correlation between the two(P<0.05),indicating that the expression of GPR50 and ADAM17 may be correlated in breast cancer.Conclusions 1 The expression of GPR50 was significantly decreased in breast cancer,but increased in breast fibroadenoma,which may be closely related to tumor inhibition and tissue fibrosis;2 The expression of ADAM17 was significantly increased in breast cancer,suggesting that ADAM17 is closely related to the occurrence and development of tumors;3 The expression of GPR50 and ADAM17 in breast cancer was significantly correlated with malignant degree and aggressiveness of the tumor,and there is a significant negative correlation between them.Figure 4;Table 5;Reference 152.